Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap | n/a |
Revenue (ttm) | n/a |
Net Income (ttm) | n/a |
Shares Out | n/a |
EPS (ttm) | n/a |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | n/a |
Last Price | n/a |
Previous Close | n/a |
Change ($) | n/a |
Change (%) | n/a |
Day's Open | n/a |
Day's Range | n/a |
Day's Volume | n/a |
52-Week Range | n/a |
News
Anebulo Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.
About ANEB
Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Our lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. There is no approved medical treatment currently available to specifically alleviate the symptoms of cannabinoid ov... [Read more...]
Industry Pharmaceutical Preparations | IPO Date Pending |
CEO Daniel Schneeberger, M.D. | Employees 2 |
Stock Exchange NASDAQ | Ticker Symbol ANEB |